Sign In
Buy RCUS
$28.42
-1.31 (-4.41%)
At Close: Jul 24, 2026
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for
Arcus Biosciences Announces New Employment Inducement Grants
04:35pm, Thursday, 09'th Oct 2025
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p
Arcus Biosciences (RCUS) Soars 8.5%: Is Further Upside Left in the Stock?
10:41am, Tuesday, 07'th Oct 2025
Arcus Biosciences (RCUS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near
How Arcus Biosciences Aims To Take On Merck In Cancer Treatment
09:51am, Tuesday, 07'th Oct 2025
Arcus Biosciences shares climbed Tuesday as enthusiasm grows for the biotech company's experimental cancer drug, a rival to Merck.
Arcus Biosciences, Inc. (RCUS) Shareholder/Analyst Call Transcript
11:15pm, Monday, 06'th Oct 2025
Arcus Biosciences, Inc. (NYSE:RCUS ) Shareholder/Analyst Call October 6, 2025 10:00 AM EDT Company Participants Pia Eaves - Vice President of Investor Relations & Strategy Terry Rosen - Co-Founder, Ch
Why Is Arcus Biosciences Stock Trading Higher On Monday?
02:23pm, Monday, 06'th Oct 2025
In the relentless quest for groundbreaking cancer therapies, innovative drug trials are reshaping treatment landscapes and redefining patient hope. Arcus Biosciences Inc. (NYSE:RCUS) on Monday announc
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p
Arcus Biosciences Announces New Employment Inducement Grants
04:35pm, Wednesday, 24'th Sep 2025
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p
Arcus Biosciences, Inc. (RCUS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
11:59am, Wednesday, 10'th Sep 2025
Arcus Biosciences, Inc. (NYSE:RCUS ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 8:30 AM EDT Company Participants Jennifer Jarrett - Chief Operating Officer Richard Mark
Arcus Biosciences Announces New Employment Inducement Grants
04:35pm, Monday, 08'th Sep 2025
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p
Arcus Biosciences, Inc. (RCUS) Presents At Citi's Biopharma Back To School Conference Transcript
05:08pm, Wednesday, 03'rd Sep 2025
Arcus Biosciences, Inc. (NYSE:RCUS ) Citi's Biopharma Back to School Conference September 3, 2025 11:15 AM EDT Company Participants Terry Rosen - Co-Founder, Chairman & CEO Jennifer Jarrett - Chief Op
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS) announced today that it will host an in-person and virtual Investor Event for analysts and investors on Monday, October 6, 2025, beginni
Arcus Biosciences to Participate in Three Upcoming Investor Conferences
04:05pm, Wednesday, 20'th Aug 2025
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patient
Jim Cramer Recommends This Energy Stock, But Don't 'Bank It All' On Arcus
08:07am, Thursday, 14'th Aug 2025
On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying Uranium Energy Corp. UEC, saying, “I like nuclear.”
Arcus Biosciences: A Risky Buy Ahead Of Pivotal, Catalyst-Rich 12 Months
09:34am, Sunday, 10'th Aug 2025
Arcus Biosciences is at a critical juncture, with multiple late-stage assets and a cash position nearly equal to its market cap. Casdatifan shows best-in-class potential in renal cell carcinoma, with
